Список проголосовавших за комментарий " Gapping up/down: AAPL +5%, AMD +5%, BAX +2% and X +1.6% after earnings, OKS +29% after M&A news, COH and AMGN +1% after upgrades; JCI -4%, ADP -3%, EA -2% and MO -1% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>OSTK</strong> +13%, <strong>ACXM</strong> +6.9%, <strong>BDN</strong> +5%, <strong>AAPL</strong> +4.7%, <strong>AMD</strong> +4.6%, <strong>AKER</strong> +4%, <strong>VNTV</strong> +3.6%, <strong>OKE</strong> +3.2%, <strong>FBHS</strong> +3.1%, (also CFO Lee Wyatt will retire)</li><li><strong>ALGN</strong> +3.1%, (also files patent infringement lawsuit against ClearCorrect and Your Smile Direct in United Kingdom), <strong>TUP</strong> +2.7%</li><li><strong>CARB</strong> +2.3%, (Carbonite acquired Double-Take Software for $65.25 mln and reports prelim Q4 results, issues FY17 guidance with Double-Take Software impact)</li><li><strong>BAX</strong> +2.3%, <strong>AVY</strong> +2.1%, <strong>X</strong> +1.6%, <strong>EQR</strong> +1.3%, <strong>USG</strong> +1.3%, <strong>ALGT</strong> +1.2%, <strong>MTSI</strong> +0.9%, <strong>ANTM</strong> +0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>OKS</strong> +28.7% (ONEOK (OKE) to acquire all of the outstanding common units of ONEOK Partners it does not already own for $9.3 bln in common stock)</li><li><strong>CERU</strong> +11.1% (announces that its Board is conducting a comprehensive review of strategic alternatives)</li><li><strong>OPHT</strong> +1.9% (initiates plan to review its strategic alternatives in order to maximize shareholder value)</li></ul><p><strong>Select Apple suppliers/related names showing strength</strong>:</p><ul><li><strong>CRUS</strong> +2.8%, <strong>SWKS</strong> +2.1%, <strong>AVGO</strong> +2.1%, <strong>MU</strong> +1%, <strong>QRVO</strong> +0.5%, <strong>QCOM</strong> +0.4%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>GALT</strong> +20.2% (says has generated sufficient financing to cover currently planned expenditures through 2017, remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December), <strong>VCEL</strong> +17.3% (announces the first implant of MACI in the US)</li><li><strong>DRYS</strong> +12.7% (DryShips confirms will release its results for the fourth quarter on February 7 after the close)</li><li><strong>XOMA</strong> +8.9% (established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery)</li><li><strong>NSTG</strong> +8.8% (announces that Humana has issued a positive coverage decision for the Prosigna Breast Cancer Gene Signature Assay)</li><li><strong>SDRL</strong> +7% (rebounding following yesterday's declines)</li><li><strong>OPXA</strong> +3.2% (further reduces workforce, terminates the employment Chief Scientific Officer)</li><li><strong>TEVA</strong> +2.3% (rebounding following yesterday's declines)</li><li><strong>MFIN</strong> +2.2% (Medallion Fincl provides long-term strategic update in ongoing transition away from medallion lending; to restructure Freshstart Venture Capital debentures, reducing Medallion exposure )</li><li><strong>PMD</strong> +2% (following late move higher after co issued press release claiming no ownership interest in Psychemedics Brasil-- still closed significantly lower)</li><li><strong>FB</strong> +1.2% (Facebook working to develop an app for TV set-top boxes, according to the WSJ )</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>IDRA</strong> +5% (assumed with a Outperform at Wedbush)</li><li><strong>MRVL</strong> +3.9% (upgraded to Buy from Sell at UBS)</li><li><strong>MRO</strong> +1.9% (upgraded to Sector Outperform from Sector Perform at Scotia)</li><li><strong>COH</strong> +1.1% (upgraded to Buy from Hold at Evercore ISI)</li><li><strong>AMGN</strong> +0.9% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>FOXA</strong> +0.8% (upgraded to Buy from Neutral at MoffettNathanson)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>BBOX</strong> -13.9%, <strong>BOOT</strong> -10.6%, <strong>MANH</strong> -7.7%, <strong>PBI</strong> -5.8%, <strong>BABY</strong> -5.2%, <strong>JCI</strong> -4.5%, <strong>MTCH</strong> -4.4%, (also sells non-dating business The Princeton Review to ST Unitas)</li><li><strong>ARAY</strong> -4.3%, <strong>TNAV</strong> -3.4%, <strong>ADP</strong> -3%, <strong>D</strong> -3%, <strong>UNVR</strong> -2.7%, (announces the sale of 15,000,000 shares of common stock by selling shareholders; sees Q4 EPS $0.23-0.27 vs $0.10 Capital IQ Consensus Estimate; revs $1.8-1.85 bln vs $1.90 bln Capital IQ Consensus Estimate )</li><li><strong>ILMN</strong> -2.4%, <strong>BBVA</strong> -2.3%, <strong>KTCC</strong> -1.8%, <strong>EA</strong> -1.7%, <strong>MDC</strong> -1.4%, <strong>MO</strong> -1.3%, <strong>NEU</strong> -1.2%, <strong>MSTR</strong> -1.1%, <strong>CACC</strong> -1.1%, <strong>OMN</strong> -1.1%, <strong>PPL</strong> -1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>CATB</strong> -65.6% (Catabasis Pharmaceuticals announces top-line safety and efficacy results for Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy)</li><li><strong>SGYP</strong> -12% (prices 20,325,204 common stock offering at $6.15/share)</li><li><strong>CCJ</strong> -10.6% (announces that Tokyo Electric Power Company Holdings has issued a termination notice for a uranium supply contract with Cameco)</li><li><strong>GALE</strong> -10.3% (Galena Biopharma announces Pres/CEO Mark W. Schwartz will resign effective today and the evaluation of strategic alternatives)</li><li><strong>UNVR</strong> -2.7% (prices previously announced public offering of 15,000,000 shares of Univar's common stock by selling shareholders at $29.00/share)</li><li><strong>MCRN</strong> -2.4% (prices offering of 12 mln shares of common stock by selling shareholders at $16.25 per share)</li><li><strong>SN</strong> -2% (prices 10 mln shares of common stock at $12.50 per share)</li><li><strong>FHB</strong> -1.1% (prices secondary offering of 25 mln shares by selling shareholders at $32.00 per share)</li><li><strong>TMHC</strong> -0.8% (prices offering of 10 mln shares of common stock at $19.00 per share)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>MBLY</strong> -3.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)</li><li><strong>NCMI</strong> -2.8% (downgraded to Underperform at Credit Suisse)</li><li><strong>GLW</strong> -1.7% (downgraded to Mkt Perform from Outperform at Bernstein)</li><li><strong>IMAX</strong> -0.6% (downgraded to Neutral from Outperform at Credit Suisse)</li></ul>"